BMAT Regulatory Frameworks & Compliance 4 — Questions and Answers
Question 1: Which of the following best describes the role of a Data Safety Monitoring Board (DSMB) in a clinical trial?
- It manages the storage and security of electronic trial data
- It independently reviews accumulating safety and efficacy data and recommends whether to continue, modify, or stop a trial (Correct answer)
- It audits financial compliance of the trial sponsor
- It recruits and randomizes participants into trial arms
Correct answer: It independently reviews accumulating safety and efficacy data and recommends whether to continue, modify, or stop a trial
A DSMB (also called IDMC) is an independent group of experts that periodically reviews unblinded safety and efficacy data to protect participant welfare and trial integrity.
Question 2: Under FDA regulations, an Investigational New Drug (IND) application must be submitted before which activity?
- Preclinical animal toxicology studies
- Initiating clinical studies of a new drug in human subjects in the U.S. (Correct answer)
- Filing a New Drug Application (NDA)
- Publishing Phase III results in a peer-reviewed journal
Correct answer: Initiating clinical studies of a new drug in human subjects in the U.S.
An IND must be in effect before administering an investigational drug to human subjects in the United States, allowing the FDA to review safety data before human exposure.
Question 3: The EU Clinical Trials Regulation (CTR 536/2014) replaced the Clinical Trials Directive and introduced which significant change?
- A single EU-wide clinical trial authorization via the CTIS portal (Correct answer)
- Mandatory placebo-controlled design for all Phase III trials
- Elimination of ethics committee review for low-risk studies
- Transfer of trial oversight exclusively to the EMA
Correct answer: A single EU-wide clinical trial authorization via the CTIS portal
CTR 536/2014 introduced the Clinical Trials Information System (CTIS), enabling sponsors to apply for authorization in multiple EU member states through a single submission.
Question 4: A company discovers that a competitor is using patented biomedical technology without a license. Under U.S. law, the primary legal remedy typically sought is:
- Filing a complaint with the FDA for market withdrawal
- Initiating patent infringement litigation in federal court seeking injunction and/or damages (Correct answer)
- Reporting the competitor to the IRB for ethical review
- Requesting the FTC investigate as an antitrust violation
Correct answer: Initiating patent infringement litigation in federal court seeking injunction and/or damages
Patent infringement claims in the U.S. are civil matters heard in federal district court, where the patent holder may seek injunctive relief and monetary damages.
Question 5: In the context of pharmaceutical regulation, what is a 'biosimilar'?
- A generic version of a small-molecule drug approved via the ANDA pathway
- A biological product highly similar to an already-approved reference biologic with no clinically meaningful differences (Correct answer)
- A counterfeit biologic product identified by the FDA
- A biologic produced by the same manufacturer under a different brand name
Correct answer: A biological product highly similar to an already-approved reference biologic with no clinically meaningful differences
A biosimilar is a biological product that is highly similar to an FDA-approved reference product, with no clinically meaningful differences in safety, purity, or potency.
Question 6: Which principle in research ethics requires that the selection of research subjects be fair and that no group bears a disproportionate burden of research risks?
- Beneficence
- Respect for Persons
- Justice (Correct answer)
- Non-maleficence
Correct answer: Justice
The principle of Justice, as articulated in the Belmont Report, requires equitable distribution of research burdens and benefits, preventing exploitation of vulnerable or marginalized populations.
Question 7: The FDA's Orphan Drug Act provides incentives to develop drugs for rare diseases affecting fewer than how many people in the U.S.?
- 10,000
- 50,000
- 200,000 (Correct answer)
- 500,000
Correct answer: 200,000
The Orphan Drug Act of 1983 defines a rare disease as one affecting fewer than 200,000 persons in the U.S., providing tax credits, extended market exclusivity, and fee waivers to sponsors.
BMAT Regulatory Frameworks & Compliance 4
Which of the following best describes the role of a Data Safety Monitoring Board (DSMB) in a clinical trial?